Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

Tiziana Life Sciences (NASDAQ:TLSA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Tiziana Life Sciences has a consensus rating of “Sell”.

Tiziana Life Sciences Price Performance

Shares of Tiziana Life Sciences stock opened at $1.24 on Friday. The firm has a 50 day simple moving average of $1.32 and a 200 day simple moving average of $1.57. Tiziana Life Sciences has a fifty-two week low of $1.01 and a fifty-two week high of $2.60.

Institutional Trading of Tiziana Life Sciences

Institutional investors have recently bought and sold shares of the business. Bison Wealth LLC acquired a new stake in Tiziana Life Sciences during the 4th quarter worth $30,000. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences during the 1st quarter worth $25,000. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences during the 4th quarter worth $25,000. ARS Investment Partners LLC acquired a new stake in Tiziana Life Sciences during the 3rd quarter worth $66,000. Finally, Zhang Financial LLC grew its holdings in Tiziana Life Sciences by 18.6% during the 4th quarter. Zhang Financial LLC now owns 99,900 shares of the company’s stock worth $149,000 after acquiring an additional 15,700 shares during the period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.